Boston Scientific price target lowered to $112 from $131 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Boston Scientific (BSX) to $112 from $131 and keeps a Buy rating on the shares. The firm said Boston Scientific reported Q4 revenue that was largely in line with expectations, though softer performance in two historically strong areas, EP and Watchma, drove weakness in the stock. Canaccord believes the company retains the growth drivers, operating discipline, and culture that defines best-in-class strategic MedTech.